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Abstract
Advanced glycation end products (AGEs) accumulate in tissues with aging and may influence age-related diseases. They
can be estimated non-invasively by skin autofluorescence (SAF) using the AGE ReaderTM. Serum 25-hydroxyvitamin D3
(25(OH)D3) may inhibit AGEs accumulation through anti-oxidative and anti-inflammatory properties but evidence in
humans is scarce. The objective was to investigate the association between serum 25(OH)D3 and SAF in the population-
based cohort study. Serum 25(OH)D3 and other covariates were measured at baseline. SAF was measured on average
11.5 years later. Known risk factors for AGE accumulation such as higher age, BMI, and coffee intake, male sex, smoking,
diabetes, and decreased renal function were measured at baseline. Linear regression models were adopted to explore the
association between 25(OH)D3 and SAF with adjustment for confounders. Interaction terms were tested to identify effect
modification. The study was conducted in the general community. 2746 community-dwelling participants (age C 45 years)
from the Rotterdam Study were included. Serum 25(OH)D3 inversely associated with SAF and explained 1.5% of the
variance (unstandardized B = - 0.002 (95% CI[- 0.003, - 0.002]), standardized b = - 0.125), independently of known
risk factors and medication intake. The association was present in both diabetics (B = - 0.004 (95% CI[- 0.008,
- 0.001]), b = - 0.192) and non-diabetics (B = - 0.002 (95% CI[- 0.003, - 0.002]), b = - 0.122), both sexes, both
smokers and non-smokers and in each RS subcohort. Serum 25(OH)D3 concentration was significantly and inversely
associated with SAF measured prospectively, also after adjustment for known risk factors for high SAF and the number of
medication used, but the causal chain is yet to be explored in future studies.
Clinical Trial Registry (1) Netherlands National Trial Register: Trial ID: NTR6831 (http://www.trialregister.nl/trialreg/
admin/rctview.asp?TC=6831). (2) WHO International Clinical Trials Registry Platform: under shared catalogue number
NTR6831 (www.who.int/ictrp/network/primary/en/).
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activated B cells
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MAR Missing at random
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Introduction
Advanced glycation end products (AGEs) are a heteroge-
neous group of highly oxidized end products formed
through non-enzymatic attachment of sugars to free amino
groups of proteins, lipids and nucleic acids [1, 2]. AGEs
accumulate in long-lived tissues with a half-life time of
many years [3]; their formation is irreversible and they are
difficult to be degraded and cleared from the tissues.
Endogenous accumulation of AGEs is accelerated under
conditions of hyperglycemia, high oxidative stress and
chronic inflammation [4]. Exogenous factors such as diet-
ary AGEs [5] and smoking-induced oxidative stress and
inhaled glycotoxins that are absorbed into the bloodstream
through the alveoli [6] also contribute to the amount of
AGEs in vivo. A decrease in renal filtration rate lowers the
clearance rate of AGEs and can thereby contribute to their
accumulation [7].
AGEs accumulation contributes to the aging process [8]
and age-related diseases [4] through formation of covalent
crosslinking of proteins in the extracellular matrix such as
collagen and elastin which lead to tissue stiffening, influ-
encing molecules’ functions by binding to active sites of
molecules, and inducing inflammation and cellular dys-
function through interaction with the receptor for AGEs
[4, 9]. They may also have genotoxic effects [10]. Aside
from the involvement in diabetic complications such as
renal insufficiency and neuropathy [11], AGEs have been
implicated in cardiovascular disease [12], bone pathology
[13], lung diseases [14], neurodegenerative diseases [15]
and some types of cancer [16].
Vitamin D and its analogs have been reported to exert
anti-inflammation effect, which could influence AGE for-
mation [17]. They were reported to prevent AGEs forma-
tion on rat cardiovascular tissue [18] and increase serum
sRAGE level which plays a role in the clearance of AGEs
as reported in human studies [19]. These studies led to the
hypothesis that vitamin D can counteract AGEs accumu-
lation but evidence for such a relation is currently still
scarce. Firstly, the laboratory studies were restricted to
particular cell types of short study duration and need cross
validation. Secondly, existing human studies were small-
scaled, cross-sectional, limited to special patient groups,
and conclusions were contradictory. In a study of 276 type
1 and type 2 diabetics and 121 non-diabetic controls, no
association was observed between 25(OH)D3 and SAF
[20]. In contrast, a significant inverse relationship between
25(OH)D3 and AGEs measured by skin autofluorescence
(SAF) was observed in a recent study of 245 type 2 dia-
betes patients treated with lifestyle advice, metformin and/
or sulphonylurea-derivatives [21]. Evidence from large
population based, prospective studies in the general pop-
ulation is lacking.
A fluorescence method has been developed to assess the
accumulation of AGEs in the human skin non-invasively
and quickly by the use of ‘‘AGE ReaderTM’’ through
measuring specific wavelength scope of skin autofluores-
cence (SAF) emitted after being excited by specific
wavelength scope of light. The fluorescent property of
AGEs has already been utilized to measure AGEs in skin
biopsies and homogenates [22]. Within the Rotterdam
study, skin AGEs have been recently measured with the
‘‘AGE ReaderTM’’ as SAF. SAF has been reported in var-
ious publications to have a positive association with dia-
betes complications and other diseases [23]. The goal of
this study was to investigate the independent association
between serum 25(OH)D3 concentration at baseline and
SAF assessed 11.5 years later in a large and densely phe-
notyped population-based cohort.
Subjects and methods
Study population
Participants were recruited from three subcohorts of the
Rotterdam Study, a population-based prospective cohort
study. It was initiated in 1990, when inhabitants of the
suburb Ommoord in the city of Rotterdam were invited to
participate. The first subcohort RS-I started in 1990,
including n = 7983 participants of 55 years and over. In
2000 a second subcohort (RS-II) started with n = 3011
participants aged 55 years and over. The third subco-
hort(RS-III) including n = 3932 participants of 45 years
and older started in 2006. All participants were examined
at baseline and every 3–5 years follow-up examinations
have been taking place. The design and objectives of the
Rotterdam Study have been extensively described
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previously [24]. The Rotterdam Study was approved by the
institutional review board (Medical ethics Committee) of
the Erasmus Medical center and by the review board of The
Netherlands Ministry of health, Welfare and Sports. All
participants in the present analysis provided written
informed consent to participate.
The AGE ReaderTM was introduced in the Rotterdam
Study to measure skin autofluorescence (SAF) in 2013, so
far 3009 participants (754 in RS-I 6th follow-up, 1088 in
RS-II 4th follow-up and 1167 in RS-III 2nd follow-up)
have SAF measurements available. Values were defined as
outliers in SAF and excluded from the analysis if it exceed
the scope of mean ± 4SD, based on this 8 participants
were excluded. 255 participants with missing value in
serum 25(OH)D3 concentration were additionally excluded
mainly because of inadequate blood sample volume for
analysis, leaving 2746 participants included in the study.
Missing value in other covariates was subsequently
checked, identifying 358 participants with incomplete data
and the other 2388 participants with full record. The
inclusion and exclusion of participants in this study are
shown in Fig. 1.
Measurement of serum 25(OH)D3 concentration
at baseline
Blood samples were collected at baseline of this research in
RS-I 3rd follow-up, RS-II 1st follow-up and RS-III 1st
visit. Serum 25(OH)D3 was assessed using electrochemi-
luminescence immunoassay (COBAS vitamin D total assay
reagent, Roche Diagnostics GmbH, Germany) measured by
MODULAR ANALYTICS, Elecsys or Cobas e
immunoassay analyzer (Roche Diagnostics GmbH, Ger-
many). The test range was between 7.5 and 175 nmol L-1
with a functional sensitivity of 10 nmol L-1. The
intermediate precision of the test was CV\ 13.1% and
within-run precision was CV\ 7.8%. The blood samples
were collected at each visit and stored in the freezer at
- 80 C until they were measured for 25(OH)D3 together
by the same techniques, instruments and tool kits in the
same time period. The concentration of 25(OH)D3 has been
adjusted for seasonal variance using cosinor analysis [25].
Assessment of covariates at baseline
All covariates were obtained at baseline when serum
25(OH)D3 was measured. Age was calculated by using the
date of birth and blood collection date. Diabetic partici-
pants were defined as having fasting blood glucose
level C 7.0 mmol L-1, or using anti-diabetes medication
or reporting to have been diagnosed with diabetes. Smok-
ing status was categorized as never, past or current smoker
based on their smoking history of cigarette, cigar and pipe
information during home interview. The anthropometric
characteristics weight and height were measured at the
research center without shoes and with light clothes, BMI
(kg/m2) was calculated as weight divided by height2. Blood
was drawn and the laboratory characteristics i.e. High-
density lipoproteins (HDL-cholesterol), total cholesterol,
triglycerides, creatinine and serum glucose were measured
through automated enzymatic method. C-reactive protein
(CRP) was measured by an immunoturbidimetric assay on
Roche/Hitachi cobas c systems. Estimated glomerular fil-
tration rate (eGFR) was calculated by the CKD-EPI
equation using serum creatine concentration, age and sex
data, expressed as a single equation:
eGFR ¼ 141min Scr=j; 1ð Þamax Scr=j; 1ð Þ1:209
 0:993Age  1:018 if female½   1:159 if black½ 
N=2746 participants
Analysis in n=2388
complete data subjects.
Participants from RS- , RS- and RS-
who were available of SAF measurement
Excluded(263):
8-outlying SAF data
255-Missing value in serum
25(OH)D3
Incomplete subjects(358):
49-Missing diabetes mellitus status
13-Missing eGFR
12-Missing BMI
39-Missing medication number
15-Missing smoking status
296-Missing coffee intake
Missing data imputed by
multiple imputation, n=2746.
Fig. 1 Flowchart of participant selection from the Rotterdam Study for the analysis in this study. Abbreviations: SAF skin auto-fluorescence;
BMI body mass index; 25(OH)D3, 25-Hydroxyvitamin D3; eGFR estimated glomerular filtration rate calculated by the CKD-EPI
Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs)…
123
where: Scr is serum creatinine in lmol/L, j is 61.9 for
females and 79.6 for males, a is - 0.329 for females and
- 0.411 for males, min indicates the minimum of Scr/j or
1, and max indicates the maximum of Scr/j or 1.
Coffee consumption data was assessed from home
interview in RS-I and RS-II and from a validated semi-
quantitative food frequency questionnaire at the Rotterdam
Study center interviewed by a trained dietician in RS-III
and expressed in g/day as a continuous variable. Grams of
coffee consumed was calculated from frequency (expressed
in cups/day), and one cup equals 150 g [26].
The total number of medication types used was calcu-
lated from the medication home interview taken by trained
research assistants. During the home interview, participants
presented all the medication they used in the past week.
Data were checked for inconsistencies by the pharmaco-
epidemiology group [27].
Measurement of SAF
SAF was assessed later with a median time interval of
14.9[5.6–15.3] (mean time interval = 11.5) years after the
25(OH)D3 measurement in RS-I 6th follow-up (15.8 years),
RS-II 4th follow-up (15.0 years) and R-III 2nd follow-up
(5.5 years). The AGE ReaderTM (DiagnOptics B.V.,
Groningen, The Netherlands) was used to determine SAF
non-invasively, which is a marker for the amount of AGEs
present in the skin. The mechanism is based on the fluores-
cent property of AGEs [28]. Meerwaldt and colleagues val-
idated the SAF for AGEs (pentosidine, carboxymethyl-
lysine (CML) and carboxyethyl-lysine (CEL)) accumulation
in skin biopsies of the same site as where SAFwas measured
[29]. Around 4 cm2 of the skin was illuminated with an
excitation light with a peak around 370 nm (between 300
and 420 nm) and guarded against surrounding light. The
emission spectrum of AGEs (420–600 nm) is measured by
the AGE Reader. SAF is calculated based on the ratio of
excitation and reflected light, expressed in arbitrary units
(A.U.), by AGE Reader software (version 2.3.0) using vali-
dated algorithm that accounts for skin color with a UV
reflectance percentage (R%) of 6–10%. Participants with a
mean skin reflectance of 6% or lower were automatically
excluded by the AGE ReaderTM.
The dominant forearm of participants was placed on the
device for three consecutive measurements of SAF. They
were asked to not use skin creams before the measurement.
Mean of three measurements was calculated to achieve
accurate SAF value. Extreme value in triple measurements
was identified and excluded through a combination of
Grubbs’ test and value outside of the mean ± 4 SD scope.
In this case, SAF was calculated as the mean of remaining
2 measurements.
Statistical analysis
Statistical methods
Statistical analyses were performed through SPSS (version
21.0). Descriptive statistics described the parameters of the
study population. Normality was determined by the use of
histograms and Q–Q plots. Depending on the normal or
non-normal distribution, data is represented as respectively
mean (± SD) or median (interquartile range, IQR). Means
of continuous variables between two groups were com-
pared via the use of Mann–Whitney U-test when a non-
normal distribution was assumed or independent samples T
test when the variable was normally distributed. v2 test was
adopted to compare the means of categorical variables.
The association of 25(OH)D3 with SAF was analyzed
via linear regression models. Simple linear regression
analyses were used to study the crude association between
a certain covariate and SAF. Multiple linear regression
analyses were conducted with SAF being the outcome,
whilst adjusting for covariates that may confound the
association or potential risk factors for high SAF (model 1
adjusted for age, sex and RS subcohorts, data not shown;
model 2 additionally adjusted for BMI, smoking status,
DM status, eGFR, coffee intake and medication numbers).
Multicollinearity was assessed by tolerance tests with a
tolerance level of 0.40 considered threshold.
Heteroscedasticity was determined by plotting the linear
regression residuals and the predicted outcome values.
Two-way interactions between age, sex, RS subcohorts,
smoking, diabetes, medication numbers, eGFR, coffee
intake and 25(OH)D3 were checked by adding interaction
terms into the linear model 2 because they were suspected
to modify the association between 25(OH)D3 and SAF. A
p value less than 0.1 was considered statistically
significant.
Subgroup analysis was conducted to see if the associa-
tion show disproportionate effects in predefined strata
(diabetes or not, smoking status, sexes, RS subcohorts).
There were missing values in covariates BMI, eGFR,
smoking, medication, diabetes status and coffee intake. To
reduce potential bias caused by including only participants
with complete information and exploit the information in
incomplete record participants, we performed multiple
imputation of missing data [30]. Missing data mechanism
was distinguished as missing at random (MAR) from
missing completely at random (MCAR) through Little’s
test and t-test. Missing values were imputed by multiple
imputations to maximize the sample size to 2746 partici-
pants. Predictive mean matching (PMM) method was used
for multiple imputation of continuous variables to avoid
implausible imputed values; for example it can be applied
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to non-normal distributed variables to avoid negative
imputed values. Logistic regression was used for categor-
ical variables. Several parameters were included in the
multiple imputation procedure to make the missing at
random assumption plausible. 20 imputations were
obtained through 20 iterations. Sensitivity analysis was
conducted to evaluate the imputation process and to see if
the association between 25(OH)D3 and SAF remain con-
sistent before and after multiple imputation. Details on the
variables imputed are shown in Online Resource 1.
Covariates which may influence the association
between 25(OH)D3 and SAF
We identified the potential risk factors for high SAF and
confounders of the association between 25(OH)D3 and SAF
at baseline based on a literature review and biological sig-
nificance. SAF is known to increase with age and BMI [31],
males showhigher SAF than females [32]. The accumulation
of AGEs is accelerated in diabetes mellitus (DM) [33] due to
e.g., hyperglycemia [11]. Participants with a lower kidney
filtration rate (indicated by eGFR) have an acceleratedAGEs
accumulation because of lower clearance rate through the
kidney. Smokers have higher SAF [32]. Coffee intake was
reported to be positively associated with SAF [32]. As an
indicator of individual health status, total number of medi-
cation administrated by each subject may be a covariate.
Cholesterol and C-reactive protein (CRP)were potential risk
factors since AGEs were accelerated formed under hyper-
lipidemia [34] and inflammation environment (indicated by
CRP). RS subcohorts were included in multiple linear
regression models coded as dummy variables to account for
potential subcohort effects. The time interval between
25(OH)D3 and SAFmeasurements varies and shares a strong
collinearity with RS subcohorts, thus RS subcohorts was
included in the models instead of time interval in order to
keep additional subcohorts information. The associations of
the above covariates with SAF were examined through
simple linear regression and they were further adjusted in
multiple linear regression models.
Results
Descriptives
Clinical and lifestyle characteristics of the total population,
diabetic and non-diabetic population are shown in Table 1.
Mean (± SD) SAF value was 2.40 (± 0.49) A.U. and mean
(± SD) serum 25(OH)D3 concentration was 64.33
(± 26.92) nmol/L. 44.0% of the participants was male and
56.0% female. SAF was higher in diabetic ((2.61 ± 0.51)
A.U.) than non-diabetic participants ((2.38 ± 0.49) A.U.).
Compared with the non-diabetic group, participants with
type 2 diabetes were older, more often male, had higher
BMI, and higher fasting serum glucose. Furthermore, dia-
betic participants had lower values of serum 25(OH)D3,
total cholesterol, HDL cholesterol and more types of
medication use.
The association between 25(OH)D3 and SAF
The crude association between parameters of interest (age,
sex, BMI, smoking status, 25(OH)D3, diabetes status,
eGFR, RS subcohorts, sum of medication used during
home interview, coffee intake, total cholesterol, CRP and
time interval) and SAF investigated through simple linear
regression is shown in Table 2. Higher SAF was signifi-
cantly related to lower 25(OH)D3, lower eGFR, male sex,
higher age, BMI and CRP, more coffee consumption,
current smoker, diabetes, use of more medications, and
longer time interval between measurements. The crude
correlation coefficient between 25(OH)D3 and SAF was
- 0.105 (p = 2.98 9 10-7), while after adjustment for
age, sex and RS subcohorts, the partial correlation coeffi-
cient was - 0.147 (p = 5.11 9 10-13). Online Resource 4
shows the crude scatterplot and correlation between
25(OH)D3 and SAF and Online Resource 5 shows the
scatter plot and partial correlation between 25(OH)D3 and
SAF after age, sex and RS subcohorts adjustment.
In the multiple linear regression model 2 (Table 2),
serum 25(OH)D3 remained significantly inversely associ-
ated with SAF (B = - 0.002, 95% CI[- 0.003, - 0.002],
standardized b = - 0.125,) after adjustment for all
covariates. Covariates were still significantly associated
with higher SAF as higher age, male sex, BMI, diabetes,
current smoker, more coffee consumption. A positive
association between medication number and SAF
(B = 0.022, 95% CI[0.012, 0.032], standardized b = 0.082)
was also found. When we adjusted for time interval instead
of RS subcohorts in model 2, the association between
25(OH)D3 and SAF was similar. No heteroscedasticity and
collinearity were detected. Variance of SAF explained by
model 2 is 19.0%, while the variance of SAF explained by
25(OH)D3 in this model was 1.5%, ranking second to sex
(3.6%), age (2.3%) and smoking (2.2%) and higher than
that of diabetes status (0.3%) and eGFR (0.1%).
Sensitivity and subgroup analysis
Multiple imputation for missing value
Comparison of the complete dataset and the imputed
dataset is shown in Online Resource 1. After multiple
imputations, average coffee consumption (g/day), but not
the other imputed variables, deviated slightly from the
Serum 25-hydroxyvitamin D3 is associated with advanced glycation end products (AGEs)…
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complete record dataset (485.05 g/day vs. 496.07 g/day ±
280.17 g/day).
Results of the multiple linear regression model 2 with
imputed data in n = 2746 participants are presented in
Online Resource 2. The coefficient of the association
between 25(OH)D3 and SAF remained the same after
multiple imputations (n = 2746, B = - 0.002, 95% CI
[- 0.003, - 0.002], p\ 0.0001) with that before multiple
imputations (n = 2388, B = - 0.002, 95% CI [- 0.003,
- 0.002], p\ 0.0001). eGFR became significantly asso-
ciated with SAF after multiple imputation. A similar
association between 25(OH)D3 and SAF was also found
(n = 358, B = - 0.003, 95% CI [- 0.004, - 0.001],
p\ 0.0001) after multiple imputation in the participants
with incomplete data.
Subgroup analysis
Results of subgroup analysis is summarized in Online
Resource 3. No significant two-way interaction was found
between diabetes status, RS subcohorts, smoking status,
sex and 25(OH)D3. Yet subgroup analysis was still con-
ducted to evaluate if the association was consistent or
disproportionate effects existed among subgroups of
participants.
The association between 25(OH)D3 and SAF remained
consistent among subgroups. There were 182 diabetic
participants out of 2388 participants. The coefficient of
serum 25(OH)D3 concentration on SAF was B = - 0.004
(95% CI [- 0.008, - 0.001], standardized coefficient
b = - 0.192) in diabetics and B = - 0.002 (95% CI
[- 0.003, - 0.002], standardized coefficient b = - 0.122)
in non-diabetics. When analyzing RS subcohorts sepa-
rately, it was noted that model 2 explained as much as
Table 1 Demographic and clinical characteristics in total population and stratified by diabetic statusa
Parameters Total population Non-diabetic group Diabetic group
N 2388 2206 (92.4%) 182 (7.6%)
Age (years) 61.19 ± 6.03 61.11 ± 6.02 62.19 ± 6.07
Sex
Male/n (%) 1050 (44.0%) 951 (43.1%) 99 (54.4%)
Female/n (%) 1338 (56.0%) 1255 (56.9%) 83 (45.6%)
BMI (kg/m2) 27.15 ± 4.03 26.92 ± 3.89 29.95 ± 4.60
Rotterdam study subcohort
RS I 606 (25.4%) 563 (25.5%) 43 (23.6%)
RS II 912 (38.2%) 833 (37.8%) 79 (43.4%)
RS III 870 (36.4%) 810 (36.7%) 60 (33.0%)
SAF (A. U.) 2.40 ± 0.49 2.38 ± 0.49 2.61 ± 0.51
25(OH)D3 (nmol/l) 64.33 ± 26.92 65.11 ± 27.06 54.87 ± 23.13
Total cholesterol (mmol/L) 5.74 ± 1.00 5.77 ± 0.99 5.41 ± 1.12
HDL cholesterol (mmol/L) 1.42 ± 0.39 1.44 ± 0.39 1.22 ± 0.34
eGFR (mL/min per 1.73 m2) 84.10 (73.78-93.78) 83.79 (73.58-93.70) 89.04 (77.06-95.82)
Smoking status, n (%)
Never smokers 735 (30.8%) 688 (31.2%) 47 (25.8%)
Ex-smokers 1185 (49.6%) 1083 (49.1%) 102 (56.0%)
Current smokers 468 (19.6%) 435(19.7%) 33 (18.1%)
Serum fasting glucose (mmol/L) 5.50 (5.10–5.90) 5.40 (5.10–5.80) 7.60 (7.10–9.025)
Medication number 1 (0–3) 1 (0–3) 2 (1–4.25)
Coffee intake (g/d) 500.00 (375.00–638.39) 500.00 (375.00–638.39) 500.00 (375.00–638.39)
C-reactive protein (mg/mL)b 1.20 (0.49–2.77) 1.10 (0.41–2.62) 1.85 (0.70, 3.53)
Time interval between 25(OH)D3 and SAF measurement (years) 14.9 (5.6–15.3) 14.9 (5.6–15.3) 14.8 (5.6–15.3)
SAF skin auto-fluorescence; BMI body mass index; 25(OH)D3 25-Hydroxyvitamin D3; HDL high-density lipoproteins; eGFR estimated
glomerular filtration rate calculated by the CKD-EPI
aNormally distributed data are expressed as mean ± standard deviation, non-normal distributed as median (interquartile range) and in the case of
nominal variables as n (%)
bn = 9 participants had missing C-reactive protein information
J. Chen et al.
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22.1% variance of SAF in RS-III, versus 13.4% and 13.6%
in RS-I and RS-II. The variance of SAF explained by
25(OH)D3 alone in model 2 was 1.8%, 0.8%, and 3.4% in
RS I, II and III respectively. The time interval between
25(OH)D3 and SAF measurements was the shortest in RS-
III. 25(OH)D3 showed a consistent association in males and
females, while the variation in SAF explained by model 2
was 19.7% in males and 12.9% in females.
Discussion
Because vitamin D may prevent AGEs accumulation
through its anti-inflammatory properties, we studied in a
large prospective cohort (the Rotterdam Study) whether
serum 25(OH)D3 concentration at baseline was associated
with AGEs in the skin assessed by SAF at follow-up. There
was a very consistent and statistically significant inverse
association in all 3 subcohorts of RS, independently of
other risk factors and potential confounders. Previously
identified factors associated with high SAF, including
higher age and BMI, male sex, diabetes, smoking and
decreased kidney function (eGFR) [32, 35, 36], were also
found to be significantly associated with high SAF in our
study. We also confirmed recent findings of a relation
between SAF and coffee consumption [35]. A novel
association was found between the number of medications
used and SAF, potentially indicating an association
between impaired health status and higher skin AGEs.
eGFR was significantly related to SAF in crude analysis,
but not after controlling for age possibly because eGFR is
correlated with age but it was significant in the multiple
linear regression models in the imputed dataset. Serum
cholesterol and CRP were no longer significantly associ-
ated with SAF in the multiple linear regression analysis so
they were not included in the full model.
The inverse association between 25(OH)D3 and SAF
was present despite a long median time interval of
14.9 years between the two measurements, which may be
explained by the long half-life time of 14.8 (95%
CI[9.4–22.3]) years of skin collagen [3]. The association
was consistent in three subcohorts and the variance of SAF
explained by 25(OH)D3 was highest in RS III, possibly
related to the shorter time interval.
A few earlier cross-sectional studies on the relationship
between 25(OH)D3 and SAF in smaller study populations
showed inconsistent results. In 276 patients with type 1 and
type 2 diabetes and 121 non-diabetic controls no associa-
tion was observed [20]. Another cross-sectional study in
119 healthy participants and 27 hypertensive patients also
reported no association [37]. In a recent preliminary report
of 245 type 2 diabetes patients treated with lifestyle advice,
metformin and/or sulphonylurea-derivatives, there was a
significant inverse relationship shown between 25(OH)D3
and SAF independently of age, season, diabetes duration
and renal function [21], consistent with our findings. Our
data extend this association to non-diabetics and the gen-
eral middle-aged and elderly population.
The observed association between 25(OH)D3 and SAF
was highly significant in the multiple linear regression
model (p = 6.89 9 10-11), and very consistent in the three
RS subcohorts but the correlation was not very strong,
explaining 1.5% of the variation. Much of the intra-indi-
vidual variation in SAF has not yet been explained. Given
the relatively small correlation coefficient we cannot
exclude the possibility that the observed association may
be related to residual confounding. However, it is of
interest that in our study in the multiple linear regression
analyses 25(OH)D3 levels explained more of the variance
in SAF (1.5%) than type 2 diabetes (0.3%) or impaired
kidney function (0.1%), which are considered well-known
predictors of AGEs accumulation apart from age and sex
[11, 38]. As participants from RS are densely phenotyped,
we were able to take into consideration many potential
confounders and the large sample size enabled good power
to detect potential confounding effects.
There are potential explanations for the inverse relation
between 25(OH)D3 and SAF. Vitamin D and its analogs
may have an effect in preventing AGEs formation or
accumulation. Salum et al. [18] recently found that oral
administration of cholecalciferol led to a decrease of AGEs
in the aortic wall of diabetic rats. Cholecalciferol and
calcitriol prevented protein glycation in vitro [39]. Cal-
citriol may indirectly help with the clearance of AGEs
through the kidney by protecting kidney structural integrity
[40]. Vitamin D plays a role in alleviating oxidative stress
[41] and inflammation response [42], which are the pre-
ferred environment for Millard reaction and AGEs
formation.
Vitamin D may also counteract the deleterious effects of
AGEs, which may indirectly reduce new AGEs formation.
AGEs can interact with its receptor RAGE and activate the
NF-jB pathway, invoking oxidative stress and inflamma-
tion [43]. Vitamin D can attenuate the activation of this
pathway through vitamin D receptor, since the receptor can
bind to IKKb protein and block NF-jB activity [44].
Vitamin D was also observed to reduce the expression of
RAGE [45]. In addition, sRAGE was shown to be
increased by vitamin D supplements in women with
polycystic ovary syndrome [19]. It acts as a decoy receptor
by binding circulating AGEs, which leads to their clearance
and prevents activation of NF-jB pathway and its ensuing
harmful effects [46]. Positive effects of vitamin D are also
supported by a previous in vitro study where calcitriol
mitigated the deleterious effect of AGEs on endothelial
cells [47]. Together with our results, these studies indicate
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a protective role of vitamin D in the accumulation and the
detrimental effects of AGEs.
Another explanation for the association of vitamin D
with SAF could be that skin AGEs may prevent the con-
version of provitamin D into vitamin D in the skin by
preventing vitamin D3 from being absorbed into the blood
or altering the extracellular matrix, blocking
photosynthesis.
Strengths of our study includes the availability of a large
and well-phenotyped population-based cohort study with a
long time interval between baseline determination of
25(OH)D3 and follow-up measurements of SAF. However,
there are also weaknesses. SAF gives a non-perfect esti-
mation of the amount of AGEs in the body. The AGE-
Reader does not measure non-fluorescent AGEs, which
also contribute to the total body AGE pool. Fluorescent
components other than AGEs may influence SAF. There
can also be local differences in AGE accumulation because
of differences in turnover rate of affected proteins [3]. We
cannot make conclusions about the causality of the inverse
association between 25(OH)D3 and SAF. Also, we are not
able yet to study a relation between SAF and incident
diseases and a potential interaction with vitamin D because
SAF was introduced in the RS recently. Serial measure-
ments of vitamin D and SAF are not available. As dis-
cussed above, we cannot exclude the possibility of residual
confounding. Also, we cannot exclude the possibility that
our results are influenced by selective survival as there is
long-term follow up in our study and elderly people and
those with impaired health at the time of vitamin D mea-
surement are most likely to drop out of the study.
In conclusion, serum 25(OH)D3 concentration measured
at baseline was inversely associated with SAF level mea-
sured years later but the causality of this relation is yet
unknown. Possible future research could investigate the
changes in 25(OH)D3 after UV-exposure in participants
with different AGEs levels. Also, studies are needed to test
whether vitamin D levels or intake may modify associa-
tions of AGEs with incident diseases. Improving vitamin D
status may lower AGE formation. Currently, some sub-
stances have been identified that may either decrease AGE
formation, such as various plant polyphenols or may reduce
the deleterious effects of AGEs such as cross-link breakers
[48]. There are several potential AGEs lowering medica-
tions under investigation [49]. More insight into the role of
AGEs and its relationship with vitamin D might provide
new opportunities for the prevention or treatment of age-
related diseases.
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